Improving health-related quality of life in non-small cell lung cancer given current treatment options: 2010 Update

David Cella*, Jyoti D. Patel

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Non-small cell lung cancer accounts for over 80% of all lung carcinomas, with the majority of patients presenting with late-stage disease. Selection of an appropriate therapy depends on the stage of disease, with treatment of advanced non-small cell lung cancer often aimed at palliation of symptoms and improving the well-being of patients. Health-related quality of life has been largely ignored as an endpoint in clinical trials for non-small cell lung cancer, but there is increasing acceptance by clinicians and regulatory authorities that alleviation of symptoms and improved health-related quality of life should be carefully considered. This article discusses current approaches to measuring health-related quality of life. This is followed by a brief review of some of the current treatment options for non-small cell lung cancer and their effect on health-related quality of life.

Original languageEnglish (US)
Pages (from-to)67-74
Number of pages8
JournalCancer and Chemotherapy Reviews
Volume5
Issue number2
StatePublished - Apr 1 2010

Keywords

  • Docetaxel
  • Erlotinib
  • Gefitinib
  • Pemetrexed
  • Second-line
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Improving health-related quality of life in non-small cell lung cancer given current treatment options: 2010 Update'. Together they form a unique fingerprint.

Cite this